Foghorn Therapeutics (FHTX)
(Delayed Data from NSDQ)
$7.60 USD
-0.35 (-4.40%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $7.50 -0.10 (-1.32%) 7:46 PM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
FHTX 7.60 -0.35(-4.40%)
Will FHTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for FHTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for FHTX
Zacks Industry Outlook Highlights Corcept, Amneal, Bioventus, Foghorn and Akebia
Wall Street Analysts Believe Foghorn Therapeutics (FHTX) Could Rally 121.77%: Here's is How to Trade
FHTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
5 Small Drug Stocks to Buy as Innovation Reaches Peak
Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Tops Revenue Estimates
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates
Other News for FHTX
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September
Flagship Pioneering and Quotient Therapeutics Announce Agreement to Identify Potential Novel Targets for the Treatment of Cardiovascular and Renal Diseases under Strategic Partnership with Pfizer
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
ZIM Integrated Shipping Services Posts Upbeat Earnings, Joins fuboTV, Foghorn Therapeutics And Other Big Stocks Moving Higher On Monday
Analysts Offer Insights on Healthcare Companies: Equillium (EQ), Foghorn Therapeutics (FHTX) and Immix Biopharma, Inc. (IMMX)